Contrasting bioAffinity Technologies (BIAF) & Its Competitors

bioAffinity Technologies (NASDAQ:BIAF) is one of 39 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its peers? We will compare bioAffinity Technologies to related businesses based on the strength of its valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Risk and Volatility

bioAffinity Technologies has a beta of 3.93, suggesting that its share price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ peers have a beta of 5.57, suggesting that their average share price is 457% more volatile than the S&P 500.

Valuation and Earnings

This table compares bioAffinity Technologies and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-2.88
bioAffinity Technologies Competitors	$1.55 billion	$101.44 million	0.11

bioAffinity Technologies’ peers have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares bioAffinity Technologies and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-249.68%	-18.81%	-11.37%

Institutional & Insider Ownership

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 52.6% of shares of all “Commercial physical research” companies are held by institutional investors. 44.3% of bioAffinity Technologies shares are held by insiders. Comparatively, 16.7% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and target prices for bioAffinity Technologies and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	50	815	1300	31	2.60

As a group, “Commercial physical research” companies have a potential upside of 5.98%. Given bioAffinity Technologies’ peers higher possible upside, analysts clearly believe bioAffinity Technologies has less favorable growth aspects than its peers.

Summary

bioAffinity Technologies peers beat bioAffinity Technologies on 9 of the 10 factors compared.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.